The European HTA Regulation is transforming market access. Our position paper explains how pharmaceutical and MedTech companies can adapt their evidence-generation strategy to succeed under the new Joint Clinical Assessment (JCA) framework across Europe and the evolving UK pathway.
Discover key insights on:
Understanding the new EU HTA Regulation and Joint Clinical Assessments (JCA)
Comparing the European and UK approaches to HTA and reimbursement
Designing integrated evidence-generation strategies from early development
Building clinical and economic evidence that meets multiple stakeholder expectations
Preparing your organization for successful market access in the new HTA landscape
